The Web Portal for Healthcare Professionals


   Medical News Center

  Home Page
Medical News Center (Home)
  Conference News
  Regulatory Affairs Middle East
  Oncology Middle East

Top 25 Hospitals
Arab World






Wednesday, 8 June 2016 | | Staff Reporter




Eastern Biotech collaborates with Fulgent Diagnostics (USA) to launch new genetic panel to identify inherited cancer

(Dubai, UAE) -- The Comprehensive Cancer Panel is a new product that analyzes 122 genes associated with the most common hereditary cancer syndromes that involve diverse cancers including breast, colorectal, endometrial, fanconi anemia, gastric, hematologic malignancy, melanoma, nervous system/brain, ovarian, pancreatic, paraganglioma-pheochromocytoma, prostate, renal/urinary, sarcoma, and thyroid.

"Next Generation Sequencing (NGS) is one of the most important technological advancements in genetic sequencing in the recent years. Eastern Biotech has ensured to choose the right set of genetic tests that incorporate this new technology, for its clients in the Middle East” says Dr Amrish Kamboj, Chief Operating Officer/Specialist Pathologist, Eastern Biotech & Life Sciences.

Additionally, Dr. Kamboj explains that the reason most individuals develop cancer later in life is due to the fact that the cancer-causing genes mutate or change over a period of time. However, some are born with a gene mutation, inherited from either parent, that predisposes them to cancer. Cancer caused by an inherited gene mutation is known as "hereditary cancer”.

Dr. Alexandra Obregon, Certified Genetic Counselor, International Outreach Program Manager at Fulgent Diagnostics, says “Early onset cancer, multiple primary cancers in the same individual, or a clear excess of certain types of cancer are suggestive of hereditary syndromes. Identifying the mutation that causes the hereditary cancer syndrome in a family allows the implementation of risk reducing protocols which improve the outcomes for these patients ”.

"We are excited to collaborate with Eastern Biotech in their efforts to facilitate genetic testing in the Middle East. We are confident that their leadership will facilitate access of Middle Eastern populations to genetic services that are showing impact in cancer prevention in other places of the world.” added Dr. Obregon.

According to Eastern Biotech, inherited genetic mutations can escalate a person’s risk of developing cancer. While average women have a 12% risk of developing breast cancer, people with a mutation that predispose them to breast cancer might have a risk above 90%; similarly, predisposition to colorectal cancer increases the base risk of 5 to 6 % to 50-100%. Once the mutation that causes hereditary cancer in a family is identified, it is possible to identify other family members at risk, even before they develop cancer, enabling primary cancer prevention. Risk reducing strategies are showing success lowering the incidence and impact of cancer in families with genetic risk.

Founded in 2005, Eastern Biotech & Life Sciences is a biotechnology company headquartered in Dubai, United Arab Emirates.

To learn more about Eastern Biotech & Life Sciences visit:



6th edition of Oman Health Exhibition & Conference | 20-22 September, 2016 | Muscat, Oman


Home  | Search | About Us  | Education  | Business  | Health Centers | Clinical Resources  | Bookstore  | LinksJob Bank | Medical News |Conference News & Analysis |
Buying Guide | Events | Products/Services Showcase | Advertise With Us | Contact Us

Copyright © 1999-2016  All rights reserved.